Online inquiry

IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11842MR)

This product GTTS-WQ11842MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets LAG3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002286.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902
UniProt ID P18627
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ11842MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8758MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IBI-101
GTTS-WQ10480MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY-2951742
GTTS-WQ3303MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ASN-100
GTTS-WQ10615MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY3300054
GTTS-WQ13939MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-2810
GTTS-WQ8740MR IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA HuPRO-140
GTTS-WQ2327MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ALXN6000
GTTS-WQ9572MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JNJ-61186372
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW